VanEck Biotech ETF (BBH)
161.79
+3.80 (+2.41%)
USD |
NASDAQ |
Aug 10, 16:00
161.32
-0.47 (-0.29%)
After-Hours: 20:00
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.35% | -0.01% | 477.52M | 16630.73 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.25% | 41.00% | 37.27M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | VanEck |
| Prospectus Benchmark Index | |
| MVIS US Listed Biotech 25 NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Peter Liao | 10.62 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
11
37.27M
-3.337B
Category Low
7.804B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of July 31, 2022
Performance Versus Category
As of August 10, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of August 10, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Amgen Inc | 12.62% | 252.09 | 1.50% |
| Vertex Pharmaceuticals Inc | 7.37% | 295.77 | -1.02% |
| Gilead Sciences Inc | 7.20% | 63.14 | 1.84% |
| Moderna Inc | 6.39% | 174.27 | 1.83% |
| Regeneron Pharmaceuticals Inc | 5.80% | 641.49 | 3.11% |
| Seagen Inc Ordinary Shares | 5.15% | 175.65 | 0.03% |
| Alnylam Pharmaceuticals Inc | 5.03% | 232.00 | 3.86% |
| IQVIA Holdings Inc | 4.97% | 239.69 | 3.05% |
| Biogen Inc | 4.46% | 221.04 | 1.59% |
| Illumina Inc | 4.33% | 227.30 | 5.82% |
News
Headline
Wire
Time (ET)
SA Breaking News
06/07 13:21
Business Wire
11/22 17:15
Basic Info
| Investment Strategy | |
| The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | VanEck |
| Prospectus Benchmark Index | |
| MVIS US Listed Biotech 25 NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Peter Liao | 10.62 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (8-10-22) | 0.25% |
| 30-Day SEC Yield (7-29-22) | Upgrade |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 14.00 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of August 09, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 12/20/2011 |
| Last Annual Report Date | 9/30/2021 |
| Last Prospectus Date | 2/1/2022 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
SA Breaking News
06/07 13:21
Business Wire
11/22 17:15